Cargando…

Applications of Alzheimer’s disease staging to clinical trials

Detalles Bibliográficos
Autores principales:	Therriault, Joseph, Gauthier, Serge, Rosa-Neto, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876645/ https://www.ncbi.nlm.nih.gov/pubmed/36622284 http://dx.doi.org/10.18632/aging.204482

Ejemplares similares

In vivo tau staging in Alzheimer’s disease
por: Therriault, Joseph, et al.
Publicado: (2022)

Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease
por: Zhang, Hua, et al.
Publicado: (2018)

The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
por: Macedo, Arthur C., et al.
Publicado: (2023)

Dynamic Amyloid and Metabolic Signatures of Delayed Recall Performance within the Clinical Spectrum of Alzheimer’s Disease
por: Tedeschi Dauar, Marina, et al.
Publicado: (2023)

Prevention strategies for Alzheimer’s disease
por: Gauthier, Serge, et al.
Publicado: (2012)

Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease
por: Ng, Kok Pin, et al.
Publicado: (2021)

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
por: Therriault, Joseph, et al.
Publicado: (2022)

Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum
por: Ng, Kok Pin, et al.
Publicado: (2022)

CCCDTD5: research diagnostic criteria for Alzheimer's Disease
por: Gauthier, Serge, et al.
Publicado: (2020)

Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
por: Fernández Arias, Jaime, et al.
Publicado: (2023)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease
por: Pascoal, Tharick A., et al.
Publicado: (2023)

Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
por: Zimmer, Eduardo Rigon, et al.
Publicado: (2014)

Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals
por: Ng, Kok Pin, et al.
Publicado: (2021)

Targeting Alzheimer’s Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment
por: Gauthier, Serge, et al.
Publicado: (2018)

Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease
por: Therriault, Joseph, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment
por: Therriault, Joseph, et al.
Publicado: (2021)

Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?
por: Ba, Maowen, et al.
Publicado: (2016)

Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals
por: Benedet, Andréa L., et al.
Publicado: (2019)

Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease
por: Terada, Tatsuhiro, et al.
Publicado: (2021)

Imaging Alzheimer's disease pathophysiology with PET
por: Schilling, Lucas Porcello, et al.
Publicado: (2016)

Anosognosia predicts default mode network hypometabolism and clinical progression to dementia
por: Therriault, Joseph, et al.
Publicado: (2018)

Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer’s disease
por: Kang, Min Su, et al.
Publicado: (2020)

Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications
por: Ferreira, Luiz Kobuti, et al.
Publicado: (2011)

Cholinergic Depletion in Alzheimer's Disease Shown by [(18)F]FEOBV Autoradiography
por: Parent, Maxime J., et al.
Publicado: (2013)

Synthesis and Comparison of the Meta-Analyses Evaluating the Efficacy of Memantine in Moderate to Severe Stages of Alzheimer’s Disease
por: Rive, Benoît, et al.
Publicado: (2013)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Clinical Neurophysiology in Alzheimer's Disease
por: Ferreri, Florinda, et al.
Publicado: (2011)

Update on the Pharmacological Treatment of Alzheimer’s Disease
por: Massoud, Fadi, et al.
Publicado: (2010)

Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease
por: Ng, Kok Pin, et al.
Publicado: (2017)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease
por: Cohen, S., et al.
Publicado: (2022)

Kundalini Yoga Intervention Increases Hippocampal Volume in Older Adults: A Pilot Randomized Controlled Trial
por: Ibrahim, Marim, et al.
Publicado: (2022)

Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
por: Savard, Melissa, et al.
Publicado: (2022)

Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease
por: Pascoal, Tharick, et al.
Publicado: (2023)

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis
por: Meyer, Pierre-François, et al.
Publicado: (2018)

Early Clinical and Molecular Detection of Alzheimer's Disease
por: Nacmias, Benedetta, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8jnaepmioe1ceh7ud6fctuhkn2